Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.Huangshan Yongsheng Tribe Stem Cell Technology Co., Ltd. (hereinafter referred to as Yongsheng Tribe Stem Cell Company) recently announced the completion of an angel round of financing worth tens of millions of yuan. The round was jointly led by JHF, founded by renowned angel investor Ms. Zhou Lixia, an early angel investor in Pop Mart, and Prosperity Investment, founded by Mr. Jiang Mingming, chairman of a well-known Chinese fund of funds. The funds from this round will be mainly used forConstruction of Huangshan Stem Cell Laboratory and Clinical Translation and Early IND Application of the Company's Core CAR-NK Immune Cell Lung Cancer Treatment Patent Technology, offering a new immunotherapy solution for patients with solid lung cancer tumors. Against the backdrop of strong national policy support for stem cell technology and a surge in cancer prevention and treatment needs, this financing event has drawn significant attention from the industry.CAR-T cell therapy is a new cancer treatment modality that has emerged in recent years and is also a research hotspot in current anti-tumor immunotherapy. The modification of immune cells through genetic engineering methods has become a trend in tumor immune cell therapy. However, there are still many obstacles for CAR-T cells in the treatment of solid tumors. For example, in terms of CAR-T cell therapy safety, off-target effects and cytokine storms often occur during treatment. Currently, all approved CAR-T products worldwide are indicated for hematological malignancies, while solid tumors remain to be addressed. CAR-NK can play a more important role in the field of solid tumor treatment.Advantages of Evertribe Stem Cell Company's Patented CAR-NK Technology in Solid Tumor Immunotherapy:1. More rapid onset: Compared with T cells, NK cells do not require antigen presentation, resulting in faster action.2. Broad-spectrum anti-tumor, NK cells have a broader spectrum of anti-tumor effects. Not restricted by MHC inhibitory activity. Suitable not only as gene-edited engineered cell therapy but also for standalone expansion and reinfusion.3. Smaller side effects: Compared with T cells, NK cells have fewer choices for HLA complexes. Autologous or allogeneic NK cells do not produce serious side effects and do not need to be immunologically matched with the patient, making them easier to apply clinically.4. Short preparation cycle, NK cells do not cause graft-versus-host disease, and multiple doses of "off-the-shelf" or "ready-to-use" CARNK cells can be prepared from one donor to treat multiple patients, thereby saving time.5. Wide sources/low cost: CAR-NK cells can be prepared from various sources such as peripheral blood, umbilical cord blood, and induced pluripotent stem cells (iPSC). Moreover, the price of "off-the-shelf" CAR-NK therapy may decrease as individual customization is not required.05 JHF Investment: Betting on the Life Science Track, Layout of Cell Drug Therapy, the Next Trillion-Dollar Enterprise Will Be Born in This FieldMs. Zhou Lixia, founding partner of JHF Investment, stated："Humanity has completed the era of creating material life needs. As people's wealth and material needs are greatly satisfied, the pursuit of longevity and health has gradually become a rigid demand. Breaking the curse of cancer is the first major hurdle for human longevity. With the rapid advancement of biotechnology in China in recent years, immune cell and stem cell therapies are becoming increasingly integrated into people's lives and disease treatments. In the field of cell therapy, many outstanding companies have emerged domestically. Two aspects attracted me to invest in Immortal Tribe Stem Cell Company: First, the company’s philosophy of using cell technology to help people live healthily, happily, and beautifully past 150 years old—a dream that I believe everyone yearns for, and certainly my own aspiration as well. Second, the founding team’s dedication to lifelong devotion to life sciences. The core founders of Immortal Tribe come from Tsinghua University's Boao and Beijing 301 expert teams, possessing cutting-edge stem cell and immune cell technologies, along with extensive experience in managing and operating cell laboratories and applying cells clinically. I believe that within the next 5-10 years, humanity will usher in an era where cancer is conquered, significantly increasing human lifespan. I hope that Immortal Tribe Stem Cell Company becomes a leader in this field."Jiang Mingming, Chairman of Shengshi Investment, said:"Dr. Hua inspires a natural sense of trust. The core founding team of Yongsheng Tribe Stem Cell Company comes from prestigious backgrounds, all hailing from Tsinghua University's Biochip Lab and the 301 Hospital. Many of his clients are beneficiaries of his life science endeavors and also staunch supporters. There is no doubt that the R&D project for new immunotherapy cancer drugs holds immense investment value. However, the research and investment cycles are extremely long, ranging from 5-8 years at the shortest to over 10 years. Fortunately, Dr. Hua is only 40 years old, very young, with ample time to realize his ambitions. Dr. Hua and his team have the courage and determination, and I am willing to be his patient capital, supporting his growth and offering him the greatest possible assistance until he achieves success."About Huangshan Yongsheng Tribe Stem Cell Technology Co., Ltd.Huangshan Yongsheng Tribe Stem Cell Technology Co., Ltd. is a life science research company specializing in the R&D and industrialization of immune cell and stem cell-based novel drugs. The core founding team comes from Tsinghua Boao and Beijing 301 Hospital. By introducing top scientists and technical teams with extensive experience in gene editing, cell drug development, and clinical research both domestically and internationally, the company combines independent innovation with the introduction of globally leading gene and cell regenerative medicine technologies. It focuses on the development of a universal CAR-NK cell platform targeting solid tumors, addressing common solid cancers such as lung cancer, thyroid cancer, liver cancer, stomach cancer, colorectal cancer, breast cancer, and cervical cancer. The company aims to provide effective gene-edited cell therapies, tumor mRNA vaccines, and organ regeneration solutions for cancer patients worldwide. Committed to leveraging gene and cell technologies, it strives to help humanity combat cancer, neurodegenerative diseases, aging, extend human lifespan, and even assist in achieving immortality.Source of the article:Yongsheng Edit Gene
